Stock Market Reviews

FGEN (FibroGen, Inc.) News

Get the latest news, insights, and market updates on FGEN (FibroGen, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Asian Dividend Stocks: Yagami And 2 Top Picks For Income
  As the Asian markets navigate a mixed economic landscape, with Japan experiencing a slight decline and China showing modest improvement in manufacturing, investors are increasingly seeking stable income opportunities through dividend stocks. In this environment, selecting stocks that offer consistent dividends can provide a reliable income stream amidst market fluctuations.
  Jan 8, 2026 - $FGEN
• FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
  Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq under the trading symbol “KYNB” effective January 8th SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it is rebranding the company to Kyntra Bio, representing the next step of the transformation of the Company and its focus on oncology and rare disease a
  Jan 7, 2026 - $FGEN
• Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration
  Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted roxadustat Orphan Drug Designation for the treatment of myelodysplastic syndromes (MDS). “The Orphan Drug Designation granted to roxadustat for MDS underscores the significant treatment gap in this indication, and highli
  Dec 15, 2025 - $FGEN
• FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
  SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15 PM ET at the Sofitel New York. Fibro
  Dec 2, 2025 - $FGEN
• Asian Dividend Stocks To Watch In Your Portfolio
  As global markets grapple with AI-related concerns and fluctuating valuations, Asian equities have not been immune to these broader economic tensions. Despite this backdrop, dividend stocks in Asia continue to attract attention for their potential to provide steady income streams amidst market volatility. In such an environment, a good stock is often characterized by its ability to maintain consistent dividend payouts while navigating economic uncertainties effectively.
  Nov 25, 2025 - $FGEN
• FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ...
  FibroGen Inc (FGEN) reports significant cost reductions and a strengthened cash position following the sale of FibroGen China, while navigating potential risks in ongoing trials.
  Nov 11, 2025 - $FGEN
• FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
  Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for the pivotal Phase 3 trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and
  Nov 10, 2025 - $FGEN
• FibroGen: Q3 Earnings Snapshot
  SAN FRANCISCO (AP) — FibroGen Inc. FGEN) on Monday reported profit of $200.6 million in its third quarter. On a per-share basis, the San Francisco-based company said it had net income of $49.61.
  Nov 10, 2025 - $FGEN
• FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates
  FibroGen (FGEN) delivered earnings and revenue surprises of +59.85% and -34.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 10, 2025 - $FGEN
• FibroGen to Report Third Quarter 2025 Financial Results
  SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial
  Nov 3, 2025 - $FGEN